中国工程科学2025，Vol.27Issue(6)：92-105,14.DOI:10.15302/J-SSCAE-2025.08.017
我国生物制药产业高质量发展现状、问题与对策
High-Quality Development of China's Biopharmaceutical Industry:Current Status,Challenges,and Strategic Measures
摘要
Abstract
The biopharmaceutical industry,serving as the core driving force in the realm of modern medicine,assumes an irreplaceable role in safeguarding national health,propelling economic development,and fostering technological advancements.When juxtaposed with the global vanguard of pharmaceutical innovation,China's pharmaceutical industry still exhibits a notable generational disparity in terms of innovation capabilities.This study analyzes the current development status of China's biopharmaceutical industry,delving into the issues and challenges encountered during its development.It also examines the development trends and competitive landscape of the international biopharmaceutical industry.Subsequently,considering China's national circumstances,this study proposes development strategies and policy recommendations for the biopharmaceutical industry in several aspects.These include intensifying policy support,bolstering innovation-driven impetus,strengthening talent cultivation,optimizing the industrial chain,and enhancing international cooperation.The overarching aim is to facilitate China's transition from a large biopharmaceutical nation to a strong biopharmaceutical power,thereby offering the public more high-quality,efficient,and accessible medical services and contributing to the construction of the Healthy China initiative.关键词
生物制药/人工智能/药物递送/细胞治疗Key words
biopharmaceuticals/artificial intelligence/drug delivery/cell therapy分类
医药卫生引用本文复制引用
徐来,余河水,王兆品,李颖,杨晶晶,陈香美,顾晓松..我国生物制药产业高质量发展现状、问题与对策[J].中国工程科学,2025,27(6):92-105,14.基金项目
中国工程院咨询项目"我国生物医药产业高质量发展战略研究"(2023-XBZD-11) Chinese Academy of Engineering project"Research on the High-Quality Development Strategy of China's Biopharmaceutical Industry"(2023-XBZD-11) （2023-XBZD-11）
